Bharat Biotech To Lead Phase 3 Trials Of Promising Shigella Vaccine

Hyderabad, June 12 (Maxim News): Bharat Biotech International Limited on Thursday announced a partnership with Pharma multinational GSK for the development and potential deployment of the Shigella vaccine candidate ‘altSonflex1-2-3‘.

Here To Join Us On WhatsApp 

The agreement marks a significant step in advancing the promising vaccine, which targets Shigellosis – a severe form of bacterial diarrhea that disproportionately affects children under five years of age, according to a press release.

The vaccine candidate ‘altSonflex1-2-3‘, developed by GSK, has shown encouraging results in early-stage clinical trials. A Phase 1 study in Europe demonstrated a favourable safety profile and a strong immune response. Subsequent Phase 2 trials in Africa, including vaccination of 9 month-old infants – the primary target population – reported no safety concerns. Interim results from 2024 confirmed that the candidate met its preset immunogenicity goals, the statement said.

Here To Join Us On WhatsApp 

Dr. Krishna Ella, Executive Chairman of Bharat Biotech, said, “With no approved vaccine currently available and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries.”

As part of the agreement, Bharat Biotech will lead further development of altSonflex1-2-3, including Phase 3 clinical trials, regulatory submissions, and large-scale manufacturing. (Maxim News)


Next Story:

Now you can get the latest stories from Indtoday on Telegram every day. Click the link to subscribe.  Click to follow Indtoday’s Facebook pageTwitter, and Instagram. For all the latest Hyderabad News updates

Leave A Reply

Your email address will not be published.